Advances in Chronic Kidney Disease
Volume 11, Issue 4 , Pages 348-356 , October 2004

Treatment of hypogonadism in men with chronic kidney disease

  • Kirsten L. Johansen

      Affiliations

    • Division of Nephrology, San Francisco VA Medical Center and University of California San Francisco, San Francisco, CA, USA
    • Corresponding Author InformationAddress correspondence to Kirsten L. Johansen, MD, San Francisco VA Medical Center, Nephrology Section, 111J, 4150 Clement Street, San Francisco, CA 94121

References 

  1. Handelsman D . Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation . Endocrine Rev . 1985;6:151–182
  2. Singh A , Norris K , Modi N , et al.   Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men . J Clin Endocrinol Metab . 2001;86:2437–2445
  3. Palmer B . Sexual dysfunction in uremia . J Am Soc Nephrol . 1999;10:1381–1388
  4. Cerqueira J , Maraes M , Glina S . Erectile dysfunction (Prevalence and associated variables in patients with chronic renal failure) . Int J Impot Res . 2002;14:65–71
  5. Procci W , Goldstein D , Aldestein J , et al.   Sexual dysfunction in the male patient with uremia (A reappraisal) . Kidney Int . 1981;19:317–323
  6. Lim V , Fang V . Gonadal dysfunction in uremic men (A study of the hypothalamo-pituitary-testicular axis before and after renal transplantation) . Am J Med . 1975;58:655–662
  7. Morales A , Lunenfeld B  International Society for the Study of the Aging Male . Investigation, treatment and monitoring of late-onset hypogonadism in males (Official recommendations of ISSAM) . Aging Male . 2002;5:74–86
  8. American Association for Clinical Endocrinologists . AACE Guidelines for evaluation and treatment of hypogonadism in adult male patients—2002 update . Endocr Pract . 2002;8:439–456
  9. Snyder P , Lawrence D . Treatment of male hypogonadism with testosterone enanthate . J Clin Endocrinol Metab . 1980;51:1335–1339
  10. Meikle A , Mazer N , Moellmer J , et al.   Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men . J Clin Endocrinol Metab . 1992;74:623–628
  11. Meikle A , Arver S , Dobs A , et al.   Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men (Influence of application site—a clinical research center study) . J Clin Endocrinol Metab . 1996;81:1832–1840
  12. Dobs A , Meikle A , Arver S , et al.   Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men . J Clin Endocrinol Metab . 1999;84:3469–3478
  13. Wang C , Swedloff R , Iranmanesh A , et al.  Testosterone Gel Study Group   Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men . J Clin Endocrinol Metab . 2000;85:2839–2853
  14. Wang C , Berman N , Longstreth J , et al.   Pharmacokinetics of transdermal testosterone gel in hypogonadal men (Application of gel at one site vs. four sites) . J Clin Endocrinol Metab . 2000;85:964–969
  15. Morley J , Perry H , Kaiser F , et al.   Effect of testosterone replacement therapy in old hypogonadal males (A preliminary study) . J Am Geriatr Soc . 1993;41:149–152
  16. Hajjar R , Kaiser F , Morley J . Outcomes of long-term testosterone replacement therapy in older hypogonadal males (A retrospective study) . J Clin Endocrinol Metab . 1997;82:3793–3796
  17. Bhasin S . The dose-dependent effects of testosterone on sexual function and on muscle mass and function . Mayo Clin Proc . 2000;75(suppl):S70–S76
  18. Bhasin S , Woodhouse L , Casaburi R , et al.   Testosterone dose-response relationships in healthy young men . Am J Physiol Endocrinol Metab . 2001;281:E1172–E1181
  19. Wang C , Alexander G , Berman N , et al.   Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study . J Clin Endocrinol Metab . 1996;81:3578–3583
  20. Morley J , Perry H . Androgen treatment of male hypogonadism in older males . J Steroid Biochem Mol Biol . 2003;85:367–373
  21. Barton C , Mirahmadi M , Vaziri N . Effects of long-term testosterone administration on pituitary-testicular axis in end-stage renal failure . Nephron . 1982;31:61–64
  22. Coevorden AV , Stolear J , Dhaene M , et al.   Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients . Clin Nephrol . 1986;26:48–54
  23. Lawrence I , Price D , Howlett T , et al.   Correcting impotence in the male dialysis patient (Experience with testosterone replacement and vacuum tumescence therapy) . Am J Kidney Dis . 1998;31:313–319
  24. Lim V , Fang V . Restoration of plasma testosterone levels in uremic men with clomiphene citrate . J Clin Endocrinol Metab . 1976;43:1370–1377
  25. Tenover J . Effects of testosterone supplementation in the aging male . J Clin Endocrinol Metab . 1992;75:1092–1098
  26. Urban R , Bodenburg C , Gilkison C , et al.   Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis . Am J Physiol . 1995;269:E820–E826
  27. Sih R , Morley J , Kaiser F , et al.   Testosterone replacement in older hypogonadal men (A 12-month randomized controlled trial) . J Clin Endocrinol Metab . 1997;82:1661–1667
  28. Bhasin S , Woodhouse L , Storer T . Androgen effects on body composition . Growth Hormone IGF Res . 2003;13(suppl):S63–S71
  29. Snyder P , Peachey H , Hannoush P , et al.   Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age . J Clin Endocrinol Metab . 1999;34:2647–2653
  30. Kenny A , Prestwood K , Gruman C , et al.   Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels . J Gerontol A Biol Sci Med Sci . 2001;56:M266–M272
  31. Ferrando A , Sheffield-Moore M , Yeckel C , et al.   Testosterone administration to older men improves muscle function (molecular and physiological mechanisms) . Am J Physiol Endocrinol Metab . 2002;282:E601–E607
  32. Katznelson L , Finkelstein J , Schoenfeld D , et al.   Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism . J Clin Endocrinol Metab . 1996;81:4358–4365
  33. Snyder P , Peachey H , Hannoush P , et al.   Effect of testosterone treatment on bone mineral density in men over 65 years of age . J Clin Endocrinol Metab . 1999;84:1966–1972
  34. Behre H , Kliesch S , Leifke E , et al.   Long-term effect of testosterone therapy on bone mineral density in hypogonadal men . J Clin Endocrinol Metab . 1997;82:2386–2390
  35. Neff M , Goldberg J , Slifkin R , et al.   A comparison of androgens for anemia in patients on hemodialysis . New Engl J Med . 1981;304:871–875
  36. Doane B , Fried W , Schwartz F . Response of uremic patients to nandrolone decanoate . Arch Intern Med . 1975;135:972–975
  37. Hendler E , Goffinet J , Ross S , et al.   Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis . N Engl J Med . 1974;291:1046–1051
  38. Cattran D , Fenton S , Wilson D , et al.   A controlled trial of nandrolone decanoate in the treatment of uremic anemia . Kidney Int . 1977;12:430–437
  39. Williams J , Stein J , Ferris T . Nandrolone decanoate therapy for patients receiving hemodialysis (A controlled study) . Arch Intern Med . 1974;134:289–293
  40. Johansen K , Mulligan K , Schambelan M . Anabolic effects of nandrolone decanoate in patients receiving dilaysis (A randomized controlled trial) . JAMA . 1999;281:1275–1281
  41. Sundaram K , Kumar N , Monder C , et al.   Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens . J Steroid Biochem Mol Biol . 1995;53:253–257
  42. Shahidi N . Androgens and erythropoiesis . N Engl J Med . 1973;289:72–80
  43. Teruel J , Marcen R , Navarro J , et al.   Evolution of serum erythropoietin after androgen administration to hemodialysis patients (A prospective study) . Nephron . 1995;70:282–286
  44. Naets J , Wittek M . The mechanism of action of androgens on erythropoiesis . Ann NY Acad Sci . 1968;149:366–376
  45. Meineke H , Crafts R . Further observations on the mechanism by which androgens and growth hormone influence erythropoiesis . Ann NY Acad Sci . 1968;149:298–307
  46. Teruel J , Aguilera A , Marcen R , et al.   Androgen therapy for anaemia of chronic renal failure (Indications in the erythropoietin era) . Scand J Urol Nephrol . 1996;30:403–408
  47. Teruel J , Marcen R , Navarro-Antolin J , et al.   Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients (A prospective study) . J Am Soc Nephrol . 1996;7:140–144
  48. Ballal S , Domoto D , Polack D , et al.   Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease . Am J Kidney Dis . 1991;17:29–33
  49. Berns J , Rudnick M , Cohen R . A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis . Clin Nephrol . 1992;37:264–267
  50. Gaughan W , Liss K , Dunn S , et al.   A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients . Am J Kidney Dis . 1997;30:495–500
  51. Lee M , Ahn S , Song J . Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin . Korean J Intern Med . 2002;17:167–173
  52. Soliman G , Oreopoulos D . Anabolic steroids and malnutrition in chronic renal failure . Peritoneal Dial Int . 1994;14:362–365
  53. Anderson F , Francis R , Peaston R , et al.   Androgen supplementation in eugonadal men with osteoporosis (Effects of six months’ treatment on markers of bone formation and resorption) . J Bone Miner Res . 1997;12:472–478
  54. Need A , Nordin B , Chatterton B . Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate . Osteoporos Int . 1993;3(suppl 1):218–222
  55. Olszynski W , Davidson KS , Adachi J , et al.   Osteoporosis in men (Epidemiology, diagnosis, prevention, and treatment) . Clin Ther . 2004;26:15–28
  56. United States Renal Data System . USRDS 2003 Annual Data Report (Atlas of End-Stage Renal Disease in the United States) . Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2003;
  57. Wu F , Eckardstein Av . Androgens and coronary artery disease . Endocr Rev . 2003;24:183–217
  58. Whitsel E , Boyko E , Matsumoto A , et al.   Intramuscular testosterone esters and plasma lipids in hypogonadal men (A meta-analysis) . Am J Med . 2001;111:261–269
  59. Dobs A , Bachorik P , Arver S , et al.   Interrelationships among lipoprotein levels, sex hormones, anthropometric paramteres, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system . J Clin Endocrinol Metab . 2001;86:1026–1033
  60. Bhasin S . Testosterone supplementation for aging-associated sarcopenia . J Gerontol A Biol Sci Med Sci . 2003;53A:1002–1008
  61. Webb C , Adamson D , Zeigler DD , et al.   Effect of acute testosterone on myocardial ischemia in men with coronary artery disease . Am J Cardiol . 1999;83:437–439
  62. Webb C , McNeill J , Hayward C , et al.   Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease . Circulation . 1999;100:1690–1696
  63. Rosano G , Leonardo F , Pagnotta P , et al.   Acute anti-ischemic effect of testosterone in men with coronary artery disease . Circulation . 1999;99:1666–1670
  64. Wu S , Weng X . Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients . Chin Med J . 1993;106:415–418
  65. English K , Steed R , Diver M , et al.   Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina . Circulation . 2000;102:1906–1911
  66. Bhasin S , Singh A , Mac R , et al.   Managing the risks of prostate disease during testosterone replacement therapy in older men (Recommendations for a standardized monitoring plan) . J Androl . 2003;24:299–311
  67. Gooren L . Androgen deficiency in the aging male (Benefits and risks of androgen supplementation) . J Steroid Biochem Mol Biol . 2003;85:349–355
  68. Behre H , Bohmeyer J , Nieschlag E . Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls . Clin Endocrinol . 1994;40:341–349
  69. Svetec D , Canby E , Thompson I , et al.   The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction . J Urol . 1997;158:1775–1777
  70. Meikle A , Arver S , Dobs A , et al.   Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system . Urology . 1997;49:191–196
  71. Swerdloff R , Wang C , Cunningham G , et al.   Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men . J Clin Endocrinol Metab . 2000;85:4500–4510

PII: S1548-5595(04)00119-3

doi: 10.1053/j.ackd.2004.07.006

Advances in Chronic Kidney Disease
Volume 11, Issue 4 , Pages 348-356 , October 2004

Article Tools